Team

Investment Committee

We are a powerful team made up of seasoned entrepreneurs, life science specialists and experienced investors who are experts at finding great ideas in which to invest. Our efforts are focused on selecting talented life sciences teams and companies with huge potential.

Matt McNamara

Chief Investment Officer & Board Director

Matt McNamara is passionate about commercialising promising human healthcare technologies. His business acumen combined with a strong background in the life sciences sector makes him one of the industry’s most credible investment voices.

Matt McNamara is passionate about commercialising promising human healthcare technologies.

His business acumen combined with a strong background in the life sciences sector makes him one of the industry’s most credible investment voices.

​Currently, Matt continues to invest in and commercialise great healthcare technologies through an exciting portfolio of executive/non-executive board and advisory roles.

​Previously, Matt spent over 30 years in the healthcare and medical sciences sector, with more than 20 years as a venture capitalist. He spent fourteen years as CIO at BioScience Managers (4 funds. $200M FUM. >20% IRR), and was previously CEO of SciCapital pre-seed fund. Prior to that he served as SVP Business Development for eBioinformatics Inc.

Early in his career, Matt spent over a decade in the Pharma industry working in sales and marketing with Merck & Co. and in general management at Johnson and Johnson Medical Pty Ltd.

​Matt has a BSc (Hons) in Molecular Biology, an MBA, and is a GAICD.

Dr Qibing Mei

Pharmacologist & Investment Committee Member

Dr Qibing Mei is a world-leading pharmacologist who has dedicated his career to leadership in new drug evaluation. His expertise has been put to impressive effect with his leadership in establishing best practice drug evaluation in China.

Dr Qibing Mei is a world-leading pharmacologist who has dedicated his career to leadership in new drug evaluation. His expertise has been put to impressive effect with his leadership in establishing best practice drug evaluation in China.

​Currently Dr Mei is Chief Scientist of the HK Biotech R&D team. He has engaged in pharmacology and new drug evaluation for 41 years and completed more than 100 pre-clinical evaluations of new drugs.

Early in his career, Dr Mei completed postdoctoral research at the University of Pennsylvania in 1991. He organised the establishment of China’s first drug-ability evaluation centre, and the certification of the first drug toxicology laboratory in Shanghai, China that complies with the OECD Principles of Good Laboratory Practice (GLP).

Additionally, he has undertaken 11 national-level projects, including the National 973 Plan, the State Project for Essential Drug Research and Development, the National 863 Project and the National Natural Science Foundation Project, and authored more than 500 publications, 130 of which are SCI papers, and 13 teaching materials and monographs.

Dr Mei has recently become an independent director of the Luzhou New Drug Evaluation and Research Centre.

Paul Field

Life Sciences Business Development Executive & Investment Committee Member

Paul Field has over 25 years of business development experience across a range of disease areas, and a deep network in the global biopharmaceutical industry.

Paul Field has over 25 years of business development experience across a range of disease areas, and a deep network in the global biopharmaceutical industry.

He is currently a corporate advisor at Alsonex, Marinova, GARDP (Switzerland), and FIND (Switzerland) and until recently a business development advisor to Biocurate.

Paul was previously the life sciences specialist at Austrade, the Australian Government’s investment promotion agency, where he facilitated foreign direct investment into Australian research of infectious diseases, autoimmune diseases, cancer and other therapeutic areas.

Paul was the founder and Executive Chairman of Bio-Link, a privately owned biotechnology business development company. His work at Bio-Link involved the commercialisation of discovery, pre-clinical and early stage clinical programs undertaken by Australian biotech companies and medical research institutions.

Paul has served on a number of Boards, and he is a Fellow of the Australian Institute of Company Directors (FAICD).

Dr Bev Thomas

Senior Investment Professional & Investment Committee Member

Dr Bev Thomas is an experienced investment, strategic and operational professional with focus on SME management. She has successfully delivered on roles in early stage venture investment, organisational turnaround and growth.

Dr Bev Thomas is an experienced investment, strategic and operational professional with focus on SME management.

She has successfully delivered on roles in early stage venture investment, organisational turnaround and growth. Dr Thomas combines Board experience on start-up investee companies and not-for-profit organisations with strong technical capabilities and commercial acumen, supporting the development and execution of successful strategic outcomes across a range of SMEs.

She is currently Director of Clean Energy Finance Corporation; an Australian clean technology venture fund with $200 million funds under management. Bev is responsible for lead identification and due diligence activities for new pipeline investment opportunities. In addition, she is an active Member of the Board of Directors for start-up investee companies.

​Previously, she was the CEO of Australia’s leading Phase I clinical faculty, Investment Manager for a large Medical Research Commercialisation Fund that supports the development of Australian life science companies with >$300 million under management.

​She holds a Ph.D and a Bachelor of Pharmacy, Upper Second Class (Hons), University of Bath, UK, and she also holds an MBA from Deakin University.

Scott Power

Investment Analyst & Investment Committee Member

Scott Power has spent the last thirty years investing in and researching emerging companies.

Scott Power has spent the last thirty years investing in and researching emerging companies.

Currently Scott is a Senior Analyst at Morgans Financial focussed on ASX listed healthcare and life science stocks. His long tenure has resulted in a wide network of contacts across the healthcare, life science and technology sectors which is essential in the identification of key trends and developments.

He has also held the role of Investment Manager in the venture capital industry at QIDC for over a decade where he helped identify and analyse large-scale investment opportunities.

​Scott has a Bachelor of Commerce, a Grad Dip Applied Finance (FINSIA) and is a Certified Practising Accountant (CPA).

Board

Mike Sullivan

Banking and Capital Markets Executive & Board Executive Chairman

Mike Sullivan is an accomplished Banking and Capital Markets Executive with experience across the US and Australia. He is an inspirational leader who brings together talented teams to drive material business advantage.

Mike Sullivan is an accomplished Banking and Capital Markets Executive with experience across the US and Australia.

He is an inspirational leader who brings together talented teams to drive material business advantage. He has an established track record of success supporting and advising growing companies and business owners.

Today, he leads a successful Corporate Advisory business supporting clients across diverse contexts and is an active investor in the life sciences sector in Australia and globally.

​Previously, he worked for 20 years in financial services across wealth management, equity capital markets, corporate advisory, and banking. His two decades’ experience includes 11 years at National Australia Bank, 3 years at Ferris Baker Watts in the US.

Mike has a Bachelor of Business Administration from Loyola College in Baltimore, Maryland USA.

Jian Sun

Entrepreneur and founder of HK Biotechnology & Board Director

Jian Sun is the Founder of Huikang Bio-Tech and Director of Huikang Group. He has a very persistent belief in the health industry and biotechnology, a forward-looking strategic vision, excellent operational capabilities, and rich management experience.

Jian Sun is the Founder of Huikang Bio-Tech and Director of Huikang Group. He has a very persistent belief in the health industry and biotechnology, a forward-looking strategic vision, excellent operational capabilities, and rich management experience.

​Over 20 years of operating and running Huikang Group, which continues to this day, Mr Sun has overseen 60 patents granted in China and abroad, more than 50 patents pending, and a number of awards for its research achievements with many of those commercialised in market, in China. At present, A$100,000,000 has been invested to create the Huikang Biotechnology Industrial Park equipped with international advanced scientific research and production equipment, covering R&D, manufacture and sale of new drugs, gene therapy, cosmetics and medical devices.

In 2005 Mr Sun started doing business in Australia, with Melbourne now the international headquarters for Huikang Group. Mr. Sun and Huikang Group are dedicated and committed biotechnology industry participants with a long-term view to being a key contributor of the global biotech industry to advance mankind.

Robin Chambers AO

Corporate Lawyer and Advisor & Board Director

Robin Chambers has a distinguished career as an international lawyer; his global perspective has resulted in leading edge experience on the negotiation and documentation of numerous joint ventures in Australia and overseas.

Robin Chambers has a distinguished career as an international lawyer; his global perspective has resulted in leading edge experience on the negotiation and documentation of numerous joint ventures in Australia and overseas.

He is currently the co-founder and Senior Partner of an Australian law firm which has a leading China and international law practice and is Chairman of China House, which is a consultancy for capital introductions on cross border investments. He has advised a number of major Chinese state-owned enterprises on their investments in Australia over a 34-year period.

Previously he has been chairman and director of ASX listed companies, General Counsel on numerous projects, including many of the major resources projects developed in Australia, as well as on projects across Asia and other continents. Robin has been involved in developing a number of funds in Australia and overseas in areas such as tourism, resources and biotech. His involvement extends to projects in more than 30 countries.

Robin has law degrees in Australia (Melbourne University) and in the USA (Duke) and is a MAICD. He received a citation in the Australian Queen’s Birthday Honour List 2012 as an Officer (AO) in the General Division of the Order of Australia, for his distinguished service to Australia-China relations, particularly in the promotion of trade and investment relationships.

Glenn Cross

Senior Corporate Advisor & Board Director

Glenn Cross has spent his career working in life sciences progressing from the lab bench to senior executive positions. His strong executive experience combined with deep laboratory experience gives him a solid understanding of the Australian and global biotech sector.

Glenn Cross has spent his career working in life sciences progressing from the lab bench to senior executive positions. His strong executive experience combined with deep laboratory experience gives him a solid understanding of the Australian and global biotech sector.

​Currently he is involved in capital markets and general investment activities in North America, Asia and Australia. He is the CEO of his own investment and advisory company Red Bluff Capital. He is also a non-executive director on the board of a number of biotechnology and medical device companies.

Previously he was the Chief Operating Officer and CEO of AusBiotech for over 13 years, and has over 40 years’ experience in the life sciences sector. Glenn has held senior executive roles in both multinational and Australian companies. His expertise covers general management, sales, marketing, finance, distribution and manufacturing in the life sciences market.

Glenn also has experience in human resources, product development and manufacturing.